# A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Adva

Source: https://onco.cc/trials/nct04370587/  
OnCo record `nct04370587` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of T3011, Pembrolizumab in melanoma, run by ImmVira Pharma Co. Ltd, now recruiting.

## Summary

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04370587 by ImmVira Pharma Co. Ltd, with 30 participants planned, started 2020-09-17 and due to reach its primary completion in 2026-09-22. Interventions recorded: T3011, T3011 + pembrolizumab. Conditions listed: Solid Tumor, Melanoma, HNSCC, Sarcoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04370587
- Phase: 1/2
- Setting: A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
- Sponsor: ImmVira Pharma Co. Ltd
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT04370587: https://clinicaltrials.gov/study/NCT04370587

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [T3011](https://onco.cc/drugs/t3011/)
- companies: [ImmVira Pharma](https://onco.cc/companies/immvira-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct04370587.json